FASLODEXTM
(fulvestrant)

FASLODEXTM is indicated as monotherapy for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

  • Not previously treated with endocrine therapy, or
  • With disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy

Faslodex is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

  • In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone agonist.

FASLODEX

FASLODEX can be used as a monotherapy or in combination with palbociclib, depending on patients' needs:
Monotherapy for the treatment of HR-positive advanced breast cancer in postmenopausal women who have:

  • Endocrine therapy-naïve, HER2-negative disease (FALCON)1
  • Disease progression following endocrine therapy or relapse on or after antioestrogen therapy (CONFIRM)2

Combination therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy:·       

  • FASLODEX in combination with palbociclib (PALOMA-3)3

HER2=human epidermal growth factor receptor 2; HR=hormone receptor.